- New management appointed, with Thomas Olin as interim CEO and Björn Petersson as CFO
- New website launched on July 16, 2026
- The Board of Directors intends to call an extraordinary general meeting. The meeting is scheduled to be held in September with the following main items on the agenda
- election of auditor
- amendment of the Articles of Incorporation to allow for the necessary capital raising for the preparation of coming clinical study
- reasons for and authorization of the aforementioned capital raising
- resolution regarding the Nomination Committee
Detailed information regarding the extraordinary general meeting will be provided in the upcoming notice.
About Novakand Pharma AB (publ)
Novakand Pharma is a clinical stage biotechnology company developing a new class of small-molecule orphan drugs for cancer.
For more information:
Visit the company’s website at www.novakand.com or contact ir@novakand.com